US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Articles published by Arvinas Inc.

< Previous 1 2 3 Next >
News headline image
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Present at Jefferies Global Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Employees Give Back During Company-wide Impact Day
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
< Previous 1 2 3 Next >